A Study of hSTC810 With Advanced/Metastatic Solid Tumors (STCUBE-001)

Inclusion Criteria: * Male or female aged at 18 ≥ years * Capable and willing to give signed informed consent * At least one measurable lesion as determined by RECIST Ver.1.1 * ECOG PS score ≤ 1 * Expected survival ≥ 12 weeks * For female or male patients of reproductive potential: Agree to use contraception throughout the study and at least 6 months after the last dose. Exclusion Criteria: * Subject who has received anti-cancer treatment within 4 weeks prior to the first dose of study treatment. * Subject who has received radiotherapy or major surgery within 4 weeks prior to screening. * Any toxicity due to prior therapy that has not resolved to ≤ Grade 1 or returned to baseline by the time of starting study treatment. * Subject with known severe (≥Grade 3) hypersensitivity to any checkpoint inhibitor. * Clinically significant laboratory abnormalities. * Subject with a history of another invasive malignancy within 3 years before the first dose of study drug. * Subject with active central nervous system (CNS) metastases. * Subject who requires high dose of steroids or other immunosuppressive medications. * Subject with a history of autoimmune disease that has required systemic treatment in the past 2 years. * Subject with active infection that requires systemic antimicrobial treatment. * Subject with active HBV or HCV infection. * Subject who has a known history of HIV infection. * Subject with active tuberculosis. * Subject with a documented history of a cerebral vascular event, unstable angina, myocardial infarction, or cardiac symptoms consistent with NYHA Class IV within 6 months prior to screening. * Subject with a history of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening CT scan. * Subject who has received a prior allogeneic stem cell or solid organ transplant. * Subject with a positive coronavirus disease (COVID) test during screening. * Subjects who have received a live attenuated vaccine within 30 days prior to screening. * Subject with another underlying medical condition.